Search

Displaying results 3521 - 3530 of 6835 in total
  1. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  2. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, Regeneron Pharmaceuticals, to amend clinical protocols to reduce the incidence of CRS. … [A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can lead to the development

  3. Drug

    Betamethasone phosphate

    go.drugbank.com/drugs/DB14669
    ApprovedVet approved

    Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible [betamethasone] to agonize glucocorticoid receptors.

  4. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_. … The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001].

  5. Drug

    Piroxicam

    go.drugbank.com/drugs/DB00554
    ApprovedInvestigational

    Its long half-life enables it to be administered once daily.

    Products: PIROXICAM CAPSULAS 2O MG
  6. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    help to curb the development of resistance to this agent. … The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas.

  7. Drug

    Pirlindole

    go.drugbank.com/drugs/DB09244
    Experimental

    Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug. … The antidepressant efficacy and safety of pirlindole have been demonstrated in numerous studies and, supported by many years of clinical experience in the treatment of depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]

  9. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder

  10. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.